On October 7, Owens & Minor, Inc. announced a definitive agreement to sell its P&HS segment along with the Owens & Minor brand. The Company completed the sale to Platinum Equity for $375 million in cash, subject to certain customary adjustments for cash, indebtedness, net working capital, and transaction expenses, and a 5% retained equity stake while also preserving tax attributes in excess of $150 million. Safe Harbor RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) (the "Company†) announc ...

Core Viewpoint - Orosur Mining Inc. has announced the admission of 666,664 common shares following the exercise of options by consultants, bringing the total number of common shares issued to 392,689,176 [1] Group 1 - The company operates as a minerals explorer and developer with projects located in Colombia and Argentina [1] - The admission of shares occurred on December 16, 2025, as part of a previously announced exercise of options [1] - No warrants were exercised during December, resulting in no additional common shares being issued from the company's block listing [1]

For investors in Owens & Minor ( OMI ), 2025 has quite frankly been a year they would like to forget. Shares have lost about 75% of their value as the company backed off an ill-conceived acquisition andOver fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a question for an article, just let me know!Analyst’s Disclosure:I/we have no s ...

Core Points - Orosur Mining Inc. has issued 666,664 common shares, representing 0.17% of the current issued share capital, following the exercise of options by consultants [1] - The exercise price for the options was C$ 0.06 per share [1] - Omar Gonzalez, the external Chief Financial Officer, exercised 166,666 options and now holds 166,666 common shares, which is 0.04% of the company's issued share capital [1]

Core Insights - Orosur Mining Inc. has reported significant progress in its exploration activities at El Pantano in Argentina and Anzá in Colombia, highlighting the discovery of a low sulphidation epithermal mineral system at El Pantano [1] Group 1: Exploration Activities - The drilling program at El Pantano has yielded assays for five holes, with notable results including PEP067, which returned 83.7 meters at 4.29 grams per tonne (g/t) of gold from surface [1] - Resource modeling and the NI43-101 report process are currently underway for the findings at El Pantano [1] Group 2: Mineral System Confirmation - The initial holes from the El Pantano drilling program have confirmed the presence of a low sulphidation epithermal mineral system, with further assays pending [1]

Group 1 - The sale of the P&HS business is now definitive, although it still requires closure and is subject to FTC review, indicating increased certainty around the transaction [1] - The company has transitioned to a pure-play Patient Direct business, which will allow for a more focused operational strategy and capital allocation [2] - With the constraints from the P&HS business removed, the company can now invest more aggressively in technology, sales, and product categories to accelerate growth [2]

Core Points - Orosur Mining Inc. has announced the posting of the Notice of Annual and Special Meeting to shareholders, which includes the Management Information Circular and proxy forms [1] - The Annual General Meeting (AGM) is scheduled for December 17, 2025, at 12:30 PM GMT in London, UK [1] - The AGM will take place at the offices of SP Angel Corporate Finance LLP, located at Prince Frederick House, 35-39 Maddox Street, London [1]

Core Points - Orosur Mining Inc. has issued 4,358,332 Common Shares, which represents 1.13% of the current issued share capital of the Company [1] - The issuance follows the exercise of 3,123,332 Restricted Stock Units (RSUs) and 1,280,000 options by directors and consultants [1] - All directors will retain their Shares and will not sell them after the exercise [1]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $697 million, up from just under $687 million in Q3 2024, with a year-to-date revenue of nearly $2.1 billion, reflecting a 3.4% increase [14][15][18] - Adjusted EBITDA for Q3 2025 was $92 million, down from $108 million in Q3 2024, impacted by a one-time revenue benefit from the previous year [16][18] - Adjusted net income per share was $0.25 for Q3 2025, compared to $0.36 in Q3 2024, while year-to-date adjusted net income per share increased to $0.80 from $0.64 [18] Business Line Data and Key Metrics Changes - Year-over-year growth was noted in sleep therapy, ostomy, and urology categories, while diabetes showed flat performance compared to Q3 2024 but improved from Q2 2025 [15][16] - The company is focusing on improving therapy adherence and expanding customer capture across its ecosystem [15] Market Data and Key Metrics Changes - The company is positioned to benefit from the growing prevalence of chronic conditions such as diabetes and sleep apnea, with over 37 million diagnosed with diabetes and an estimated 85 million adults affected by obstructive sleep apnea in the U.S. [8][9] Company Strategy and Development Direction - The company announced a definitive agreement to sell its Products and Healthcare Services segment to Platinum Equity, allowing it to focus on its Patient Direct business and home-based care [5][6] - Future investments will prioritize technology and automation to enhance patient experience and operational efficiency [9][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the home-based care business and the potential for growth following the divestiture, emphasizing a unified strategic focus [11][22] - The company anticipates a strong 2026, despite a significant customer loss, and plans to manage operational costs and improve cash flow [27][30] Other Important Information - The company expects to incur approximately $40 million in annualized stranded costs from the divestiture [18] - As of September 30, net debt was $2.1 billion, with expectations for slight reduction by year-end [19][20] Q&A Session Summary Question: Durability of trends going into 2026 and selling into the Optum channel - Management indicated that the Optum channel is new and expected to create more opportunities, with guidance for 2026 to be provided closer to year-end [26][27] Question: Outlook for 2026 and free cash flow trends - Management expects decent top-line growth and margin improvement in 2026, with free cash flow trends anticipated to remain stable despite some one-off costs [30][32] Question: Details on preferred provider agreements and filling the Kaiser contract loss - Management noted that it would take less revenue growth to cover the loss of the Kaiser contract due to its low margin nature, and emphasized the importance of preferred provider agreements [37][39] Question: Clarification on cash flow and balance sheet issues - Management explained that cash flow challenges were related to startup costs of a new kitting facility and over-acquired inventory, which are expected to normalize over time [40][42]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $697 million, up from nearly $687 million in Q3 2024, with a notable one-time revenue benefit of $6 million in the previous year impacting growth rates [15][19] - Adjusted EBITDA for Q3 2025 was $92 million, down from $108 million in Q3 2024, affected by the same one-time benefit and increased product costs [17][19] - Adjusted net income per share was $0.25 compared to $0.36 in 2024, while year-to-date adjusted net income per share was $0.80 versus $0.64 in the same period last year [19] Business Line Data and Key Metrics Changes - Key categories showing year-over-year growth included sleep therapy, ostomy, and urology, while diabetes revenue remained nearly flat compared to 2024 [15][16] - The company is focusing on improving therapy adherence and expanding customer capture across its ecosystem to drive stronger diabetes growth [16] Market Data and Key Metrics Changes - The U.S. market has over 37 million diagnosed diabetes patients and approximately 85 million adults with some degree of obstructive sleep apnea (OSA), presenting significant growth opportunities for the company [8][9] - The company is actively collaborating with industry partners to maintain a strong dialogue regarding competitive bidding programs in home-based healthcare [10] Company Strategy and Development Direction - The company announced a definitive agreement to sell its Products and Healthcare Services segment, allowing it to focus solely on the home-based care business [5][6] - Future investments will prioritize technology and automation to enhance customer experience and operational efficiency [7][8] - The company aims to improve cash flow and financial flexibility by prioritizing debt repayment following the divestiture [6][11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future as a pure-play home-based care company, anticipating strong organic growth and improved cash flow despite the loss of a large customer contract [26][30] - The company expects to maintain compliance with covenants and remain financially stable post-divestiture [33] Other Important Information - Year-to-date stranded costs were $25 million, down from $39 million in the same period in 2024, with expectations of annualized stranded costs around $40 million [19] - The company reported $28 million of free cash flow in Q3 and $78 million for the first nine months of the year [22] Q&A Session Summary Question: How should the company think about the durability of trends going into 2026? - Management indicated that while they cannot provide specific 2026 data yet, they expect strong trends to continue, barring a significant customer loss [24][26] Question: What is the outlook for free cash flow in 2025 and beyond? - Management expects Q4 to resemble Q3 in terms of free cash flow, with improvements anticipated in 2026 due to the loss of a less profitable contract [30][31] Question: Are there any risks to covenants post-divestiture? - Management confirmed that they are in compliance with covenants and expect to remain so [33] Question: How do preferred vendor agreements work, and how will the company fill the gap from the lost contract? - Management stated that it will take fewer contracts to cover the lost contract's EBITDA and cash flow, emphasizing the favorable margins of new agreements [36][41] Question: Can you elaborate on the cash flow issues related to the new kitting facility? - Management explained that startup costs and over-acquired inventory for the new facility are impacting cash flow, but these issues are expected to resolve in the coming months [42][44]